Microalbuminuria on admission for acute exacerbation of COPD as a predictor of all-cause mortality and future exacerbations

Microalbuminuria (MAB) is a sensitive biomarker of cardiovascular risk that is directly associated with cardiovascular events and mortality. Recent studies have evaluated the presence of MAB in patients with stable chronic obstructive pulmonary disease (COPD) or hospitalised for acute exacerbation o...

Full description

Saved in:
Bibliographic Details
Published in:Postgraduate medical journal 2023-05, Vol.99 (1169), p.189
Main Authors: Bartziokas, Konstantinos, Kyriakopoulos, Christos, Dounousi, Evangelia, Kostikas, Konstantinos
Format: Article
Language:English
Subjects:
Albumins
Forced Expiratory Volume
Hospitalization
Humans
Kaplan-Meier Estimate
Pulmonary Disease, Chronic Obstructive
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 1169
container_start_page 189
container_title Postgraduate medical journal
container_volume 99
creator Bartziokas, Konstantinos
Kyriakopoulos, Christos
Dounousi, Evangelia
Kostikas, Konstantinos
description Microalbuminuria (MAB) is a sensitive biomarker of cardiovascular risk that is directly associated with cardiovascular events and mortality. Recent studies have evaluated the presence of MAB in patients with stable chronic obstructive pulmonary disease (COPD) or hospitalised for acute exacerbation of COPD (AECOPD). We evaluated 320 patients admitted for AECOPD in respiratory medicine departments of two tertiary hospitals. On admission, demographic, clinical and laboratory values and COPD severity were assessed. Patients were evaluated monthly for 1 year, recording new AECOPD and death from any cause. Patients with documented MAB (urinary albumin excretion of 30-300 mg/24 hours) on admission had worse lung function (forced expiratory volume in 1 s, %) (mean (SD) 34.2 (13.6)% vs 61.5 (16.7)%), higher modified Medical Research Council (3.6 (1.2) vs 2.1 (0.8)), lower 6 min walk test (171 (63) vs 366 (104)) and more hospitalisation days (9 (2.8) vs 4.7 (1.9)) (p 
doi_str_mv 10.1136/postgradmedj-2021-141206
format article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_37222052</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>37222052</sourcerecordid><originalsourceid>FETCH-LOGICAL-p108t-38a4db3c856ec83f209929145e5af83dfb178d11b1de91fdf7e7263ae1491b073</originalsourceid><addsrcrecordid>eNpVkMtKxDAYhYMgzjj6CpIXiOZP2qZdyngFZVzoevhzkwzttOQCDr68FXXh6hwOh2_xEUKBXwLI5moaU36PaAdnd0xwAQwqELw5Ikuomo5xVTcLcprSjnOQqoITspBKCMFrsSSfz8HEEXtdhrAvMSAd93SGhZTC3PwYKZqSHXUfaFzUmL_n0dP15uWGYqJIp-hsMHl-zjP2PTNYkqPDGDP2IR8o7i31JZf4n5LOyLHHPrnz31yRt7vb1_UDe9rcP66vn9gEvM1MtlhZLU1bN8600gvedaKDqnY1-lZar0G1FkCDdR1465VTopHooOpAcyVX5OKHOxU9W9pOMQwYD9s_C_IL_Z5jPA</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Microalbuminuria on admission for acute exacerbation of COPD as a predictor of all-cause mortality and future exacerbations</title><source>Oxford Journals Online</source><creator>Bartziokas, Konstantinos ; Kyriakopoulos, Christos ; Dounousi, Evangelia ; Kostikas, Konstantinos</creator><creatorcontrib>Bartziokas, Konstantinos ; Kyriakopoulos, Christos ; Dounousi, Evangelia ; Kostikas, Konstantinos</creatorcontrib><description><![CDATA[Microalbuminuria (MAB) is a sensitive biomarker of cardiovascular risk that is directly associated with cardiovascular events and mortality. Recent studies have evaluated the presence of MAB in patients with stable chronic obstructive pulmonary disease (COPD) or hospitalised for acute exacerbation of COPD (AECOPD). We evaluated 320 patients admitted for AECOPD in respiratory medicine departments of two tertiary hospitals. On admission, demographic, clinical and laboratory values and COPD severity were assessed. Patients were evaluated monthly for 1 year, recording new AECOPD and death from any cause. Patients with documented MAB (urinary albumin excretion of 30-300 mg/24 hours) on admission had worse lung function (forced expiratory volume in 1 s, %) (mean (SD) 34.2 (13.6)% vs 61.5 (16.7)%), higher modified Medical Research Council (3.6 (1.2) vs 2.1 (0.8)), lower 6 min walk test (171 (63) vs 366 (104)) and more hospitalisation days (9 (2.8) vs 4.7 (1.9)) (p < 0.001 for all comparisons). MAB was also correlated with Global Initiative for Chronic Obstructive Lung Disease 2020 COPD stages (p < 0.001). In multivariate regression analysis, MAB was a significant predictor of longer hospitalisation duration (OR 6.847, 95% CI 3.050 to 15.370, p < 0.0001). Twelve-month follow-up revealed that patients with MAB experienced more AECOPDs (4.6 (3.6) vs 2.2 (3.5), p < 0.0001) and deaths, n (%) (52 (36.6) vs 14 (7.8), p < 0.001). Kaplan-Meier survival curves demonstrated that patients with MAB presented with increased mortality, AECOPD and hospitalisation for AECOPD risk at 1 year (p < 0.001 for all comparisons). The presence of MAB on admission for AECOPD was associated with more severe COPD and prolonged hospitalisation, as well as with higher rates of AECOPD and mortality risk at 1-year follow-up.]]></description><identifier>EISSN: 1469-0756</identifier><identifier>DOI: 10.1136/postgradmedj-2021-141206</identifier><identifier>PMID: 37222052</identifier><language>eng</language><publisher>England</publisher><subject>Albumins ; Forced Expiratory Volume ; Hospitalization ; Humans ; Kaplan-Meier Estimate ; Pulmonary Disease, Chronic Obstructive</subject><ispartof>Postgraduate medical journal, 2023-05, Vol.99 (1169), p.189</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of Postgraduate Medical Journal. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0003-0774-3942 ; 0000-0002-9657-3705 ; 0000-0001-8806-2561</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37222052$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bartziokas, Konstantinos</creatorcontrib><creatorcontrib>Kyriakopoulos, Christos</creatorcontrib><creatorcontrib>Dounousi, Evangelia</creatorcontrib><creatorcontrib>Kostikas, Konstantinos</creatorcontrib><title>Microalbuminuria on admission for acute exacerbation of COPD as a predictor of all-cause mortality and future exacerbations</title><title>Postgraduate medical journal</title><addtitle>Postgrad Med J</addtitle><description><![CDATA[Microalbuminuria (MAB) is a sensitive biomarker of cardiovascular risk that is directly associated with cardiovascular events and mortality. Recent studies have evaluated the presence of MAB in patients with stable chronic obstructive pulmonary disease (COPD) or hospitalised for acute exacerbation of COPD (AECOPD). We evaluated 320 patients admitted for AECOPD in respiratory medicine departments of two tertiary hospitals. On admission, demographic, clinical and laboratory values and COPD severity were assessed. Patients were evaluated monthly for 1 year, recording new AECOPD and death from any cause. Patients with documented MAB (urinary albumin excretion of 30-300 mg/24 hours) on admission had worse lung function (forced expiratory volume in 1 s, %) (mean (SD) 34.2 (13.6)% vs 61.5 (16.7)%), higher modified Medical Research Council (3.6 (1.2) vs 2.1 (0.8)), lower 6 min walk test (171 (63) vs 366 (104)) and more hospitalisation days (9 (2.8) vs 4.7 (1.9)) (p < 0.001 for all comparisons). MAB was also correlated with Global Initiative for Chronic Obstructive Lung Disease 2020 COPD stages (p < 0.001). In multivariate regression analysis, MAB was a significant predictor of longer hospitalisation duration (OR 6.847, 95% CI 3.050 to 15.370, p < 0.0001). Twelve-month follow-up revealed that patients with MAB experienced more AECOPDs (4.6 (3.6) vs 2.2 (3.5), p < 0.0001) and deaths, n (%) (52 (36.6) vs 14 (7.8), p < 0.001). Kaplan-Meier survival curves demonstrated that patients with MAB presented with increased mortality, AECOPD and hospitalisation for AECOPD risk at 1 year (p < 0.001 for all comparisons). The presence of MAB on admission for AECOPD was associated with more severe COPD and prolonged hospitalisation, as well as with higher rates of AECOPD and mortality risk at 1-year follow-up.]]></description><subject>Albumins</subject><subject>Forced Expiratory Volume</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Pulmonary Disease, Chronic Obstructive</subject><issn>1469-0756</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpVkMtKxDAYhYMgzjj6CpIXiOZP2qZdyngFZVzoevhzkwzttOQCDr68FXXh6hwOh2_xEUKBXwLI5moaU36PaAdnd0xwAQwqELw5Ikuomo5xVTcLcprSjnOQqoITspBKCMFrsSSfz8HEEXtdhrAvMSAd93SGhZTC3PwYKZqSHXUfaFzUmL_n0dP15uWGYqJIp-hsMHl-zjP2PTNYkqPDGDP2IR8o7i31JZf4n5LOyLHHPrnz31yRt7vb1_UDe9rcP66vn9gEvM1MtlhZLU1bN8600gvedaKDqnY1-lZar0G1FkCDdR1465VTopHooOpAcyVX5OKHOxU9W9pOMQwYD9s_C_IL_Z5jPA</recordid><startdate>20230519</startdate><enddate>20230519</enddate><creator>Bartziokas, Konstantinos</creator><creator>Kyriakopoulos, Christos</creator><creator>Dounousi, Evangelia</creator><creator>Kostikas, Konstantinos</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><orcidid>https://orcid.org/0000-0003-0774-3942</orcidid><orcidid>https://orcid.org/0000-0002-9657-3705</orcidid><orcidid>https://orcid.org/0000-0001-8806-2561</orcidid></search><sort><creationdate>20230519</creationdate><title>Microalbuminuria on admission for acute exacerbation of COPD as a predictor of all-cause mortality and future exacerbations</title><author>Bartziokas, Konstantinos ; Kyriakopoulos, Christos ; Dounousi, Evangelia ; Kostikas, Konstantinos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p108t-38a4db3c856ec83f209929145e5af83dfb178d11b1de91fdf7e7263ae1491b073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Albumins</topic><topic>Forced Expiratory Volume</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Pulmonary Disease, Chronic Obstructive</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bartziokas, Konstantinos</creatorcontrib><creatorcontrib>Kyriakopoulos, Christos</creatorcontrib><creatorcontrib>Dounousi, Evangelia</creatorcontrib><creatorcontrib>Kostikas, Konstantinos</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Postgraduate medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bartziokas, Konstantinos</au><au>Kyriakopoulos, Christos</au><au>Dounousi, Evangelia</au><au>Kostikas, Konstantinos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Microalbuminuria on admission for acute exacerbation of COPD as a predictor of all-cause mortality and future exacerbations</atitle><jtitle>Postgraduate medical journal</jtitle><addtitle>Postgrad Med J</addtitle><date>2023-05-19</date><risdate>2023</risdate><volume>99</volume><issue>1169</issue><spage>189</spage><pages>189-</pages><eissn>1469-0756</eissn><abstract><![CDATA[Microalbuminuria (MAB) is a sensitive biomarker of cardiovascular risk that is directly associated with cardiovascular events and mortality. Recent studies have evaluated the presence of MAB in patients with stable chronic obstructive pulmonary disease (COPD) or hospitalised for acute exacerbation of COPD (AECOPD). We evaluated 320 patients admitted for AECOPD in respiratory medicine departments of two tertiary hospitals. On admission, demographic, clinical and laboratory values and COPD severity were assessed. Patients were evaluated monthly for 1 year, recording new AECOPD and death from any cause. Patients with documented MAB (urinary albumin excretion of 30-300 mg/24 hours) on admission had worse lung function (forced expiratory volume in 1 s, %) (mean (SD) 34.2 (13.6)% vs 61.5 (16.7)%), higher modified Medical Research Council (3.6 (1.2) vs 2.1 (0.8)), lower 6 min walk test (171 (63) vs 366 (104)) and more hospitalisation days (9 (2.8) vs 4.7 (1.9)) (p < 0.001 for all comparisons). MAB was also correlated with Global Initiative for Chronic Obstructive Lung Disease 2020 COPD stages (p < 0.001). In multivariate regression analysis, MAB was a significant predictor of longer hospitalisation duration (OR 6.847, 95% CI 3.050 to 15.370, p < 0.0001). Twelve-month follow-up revealed that patients with MAB experienced more AECOPDs (4.6 (3.6) vs 2.2 (3.5), p < 0.0001) and deaths, n (%) (52 (36.6) vs 14 (7.8), p < 0.001). Kaplan-Meier survival curves demonstrated that patients with MAB presented with increased mortality, AECOPD and hospitalisation for AECOPD risk at 1 year (p < 0.001 for all comparisons). The presence of MAB on admission for AECOPD was associated with more severe COPD and prolonged hospitalisation, as well as with higher rates of AECOPD and mortality risk at 1-year follow-up.]]></abstract><cop>England</cop><pmid>37222052</pmid><doi>10.1136/postgradmedj-2021-141206</doi><orcidid>https://orcid.org/0000-0003-0774-3942</orcidid><orcidid>https://orcid.org/0000-0002-9657-3705</orcidid><orcidid>https://orcid.org/0000-0001-8806-2561</orcidid></addata></record>
fulltext fulltext
identifier EISSN: 1469-0756
ispartof Postgraduate medical journal, 2023-05, Vol.99 (1169), p.189
issn 1469-0756
language eng
recordid cdi_pubmed_primary_37222052
source Oxford Journals Online
subjects Albumins
Forced Expiratory Volume
Hospitalization
Humans
Kaplan-Meier Estimate
Pulmonary Disease, Chronic Obstructive
title Microalbuminuria on admission for acute exacerbation of COPD as a predictor of all-cause mortality and future exacerbations
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T00%3A04%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Microalbuminuria%20on%20admission%20for%20acute%20exacerbation%20of%20COPD%20as%20a%20predictor%20of%20all-cause%20mortality%20and%20future%20exacerbations&rft.jtitle=Postgraduate%20medical%20journal&rft.au=Bartziokas,%20Konstantinos&rft.date=2023-05-19&rft.volume=99&rft.issue=1169&rft.spage=189&rft.pages=189-&rft.eissn=1469-0756&rft_id=info:doi/10.1136/postgradmedj-2021-141206&rft_dat=%3Cpubmed%3E37222052%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p108t-38a4db3c856ec83f209929145e5af83dfb178d11b1de91fdf7e7263ae1491b073%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/37222052&rfr_iscdi=true